Related Experiment Video
Updated: Aug 26, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4
Adrien Bertrand-Chapel1, Cassandre Caligaris1, Tanguy Fenouil2,3
1TGF-β & Pancreatic Cancer Lab, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, INSERM 1052, CNRS 5286, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Abstract:
TGF-β signaling is involved in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis, representing one of the four major pathways genetically altered in 100% of PDAC cases. TGF-β exerts complex and pleiotropic effects in cancers, notably via the activation of SMAD pathways, predominantly SMAD2/3/4. Though SMAD2 and 3 are rarely mutated in cancers, SMAD4 is lost in about 50% of PDAC, and the role of SMAD2/3 in a SMAD4-null context remains understudied. We herein provide evidence of a SMAD2/3 oncogenic effect in response to TGF-β1 in SMAD4-null human PDAC cancer cells. We report that inactivation of SMAD2/3 in SMAD4-negative PDAC cells compromises TGF-β-driven collective migration mediated by FAK and Rho/Rac signaling. Moreover, RNA-sequencing analyses highlight a TGF-β gene signature related to aggressiveness mediated by SMAD2/3 in the absence of SMAD4. Using a PDAC patient cohort, we reveal that SMAD4-negative tumors with high levels of phospho-SMAD2 are more aggressive and have a poorer prognosis. Thus, loss of SMAD4 tumor suppressive activity in PDAC leads to an oncogenic gain-of-function of SMAD2/3, and to the onset of associated deleterious effects.
Insights
In pancreatic cancer (PDAC), loss of SMAD4 allows SMAD2/3 to promote tumor growth and spread. Targeting SMAD2/3 may offer new therapeutic strategies for aggressive PDAC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling Pathways
Background:
- Transforming Growth Factor-beta (TGF-β) signaling is crucial in pancreatic ductal adenocarcinoma (PDAC) development.
- SMAD4 is frequently lost in PDAC, but the role of SMAD2/3 in SMAD4-deficient PDAC remains unclear.
Purpose of the Study:
- To investigate the oncogenic role of SMAD2/3 in SMAD4-null PDAC cells.
- To elucidate the mechanisms by which SMAD2/3 signaling contributes to PDAC aggressiveness.
Main Methods:
- Utilized SMAD4-negative human PDAC cell lines.
- Performed TGF-β1 stimulation and inactivation of SMAD2/3.
- Conducted RNA-sequencing and analyzed phospho-SMAD2 levels in PDAC patient tumors.
Main Results:
- SMAD2/3 activation drives TGF-β1-induced collective cell migration via FAK and Rho/Rac signaling in SMAD4-null PDAC cells.
- A TGF-β gene signature associated with SMAD2/3-driven aggressiveness was identified.
- SMAD4-negative PDAC tumors with high phospho-SMAD2 expression correlate with poorer prognosis.
Conclusions:
- Loss of SMAD4 tumor suppressor function in PDAC results in an oncogenic gain-of-function for SMAD2/3.
- SMAD2/3 signaling contributes to PDAC aggressiveness and poor patient outcomes.
More Related Videos
11:38Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay
Published on: September 14, 2021
11:06Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
Published on: July 30, 2018
Related Concept Videos
TGF - β Signaling Pathway
Hedgehog Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway